158 related articles for article (PubMed ID: 15155467)
1. CD19-targeting liposomes containing imatinib efficiently kill Philadelphia chromosome-positive acute lymphoblastic leukemia cells.
Harata M; Soda Y; Tani K; Ooi J; Takizawa T; Chen M; Bai Y; Izawa K; Kobayashi S; Tomonari A; Nagamura F; Takahashi S; Uchimaru K; Iseki T; Tsuji T; Takahashi TA; Sugita K; Nakazawa S; Tojo A; Maruyama K; Asano S
Blood; 2004 Sep; 104(5):1442-9. PubMed ID: 15155467
[TBL] [Abstract][Full Text] [Related]
2. The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate.
Kuroda J; Kimura S; Segawa H; Kobayashi Y; Yoshikawa T; Urasaki Y; Ueda T; Enjo F; Tokuda H; Ottmann OG; Maekawa T
Blood; 2003 Sep; 102(6):2229-35. PubMed ID: 12763930
[TBL] [Abstract][Full Text] [Related]
3. In vitro drug resistance to imatinib and mutation of ABL gene in childhood Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.
Kawaguchi H; Taketani T; Hongo T; Park MJ; Koh K; Ida K; Kobayashi M; Takita J; Taki T; Yoshino H; Bessho F; Hayashi Y
Leuk Lymphoma; 2005 Feb; 46(2):273-6. PubMed ID: 15621812
[TBL] [Abstract][Full Text] [Related]
4. Imatinib and leptomycin B are effective in overcoming imatinib-resistance due to Bcr-Abl amplification and clonal evolution but not due to Bcr-Abl kinase domain mutation.
Kancha RK; von Bubnoff N; Miething C; Peschel C; Götze KS; Duyster J
Haematologica; 2008 Nov; 93(11):1718-22. PubMed ID: 18728023
[TBL] [Abstract][Full Text] [Related]
5. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.
Chu S; Holtz M; Gupta M; Bhatia R
Blood; 2004 Apr; 103(8):3167-74. PubMed ID: 15070699
[TBL] [Abstract][Full Text] [Related]
6. INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity.
Yokota A; Kimura S; Masuda S; Ashihara E; Kuroda J; Sato K; Kamitsuji Y; Kawata E; Deguchi Y; Urasaki Y; Terui Y; Ruthardt M; Ueda T; Hatake K; Inui K; Maekawa T
Blood; 2007 Jan; 109(1):306-14. PubMed ID: 16954504
[TBL] [Abstract][Full Text] [Related]
7. In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia.
La Rosée P; Johnson K; O'Dwyer ME; Druker BJ
Exp Hematol; 2002 Jul; 30(7):729-37. PubMed ID: 12135670
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of imatinib in cells from patients with adult acute lymphoblastic leukemia.
Hallböök H; Barbany G; Aleskog A; Björnberg A; Larsson R; Sundström C; Lindhagen E
Anticancer Drugs; 2005 Jul; 16(6):631-4. PubMed ID: 15930891
[TBL] [Abstract][Full Text] [Related]
9. Identification of heat shock protein 32 (Hsp32) as a novel target in acute lymphoblastic leukemia.
Cerny-Reiterer S; Meyer RA; Herrmann H; Peter B; Gleixner KV; Stefanzl G; Hadzijusufovic E; Pickl WF; Sperr WR; Melo JV; Maeda H; Jäger U; Valent P
Oncotarget; 2014 Mar; 5(5):1198-211. PubMed ID: 24681707
[TBL] [Abstract][Full Text] [Related]
10. ABL-specific tyrosine kinase inhibitor, STI571 in vitro, affects Ph-positive acute lymphoblastic leukemia and chronic myelogenous leukemia in blastic crisis.
Nakajima A; Tauchi T; Ohyashiki K
Leukemia; 2001 Jun; 15(6):989-90. PubMed ID: 11417489
[No Abstract] [Full Text] [Related]
11. Restoration of INK4a/ARF gene inhibits cell growth and cooperates with imatinib mesylate in Philadelphia chromosome-positive leukemias.
Bai Y; Lu Z; Lin Y; Sun B; Wang S; Wang G
Oncol Res; 2013; 21(1):23-31. PubMed ID: 24330849
[TBL] [Abstract][Full Text] [Related]
12. [The anti-leukemic effects of imatinib, daunorubicin and bortezomib on two leukemia cell lines with Ph(+)].
Yang X; Yang L; Gong YP; Chang H; Zhou RQ; Xing HY; Zheng BH
Sichuan Da Xue Xue Bao Yi Xue Ban; 2010 Sep; 41(5):793-6. PubMed ID: 21302443
[TBL] [Abstract][Full Text] [Related]
13. Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571.
Klejman A; Rushen L; Morrione A; Slupianek A; Skorski T
Oncogene; 2002 Aug; 21(38):5868-76. PubMed ID: 12185586
[TBL] [Abstract][Full Text] [Related]
14. Response: Co-administration of cyclosporine A and imatinib among patients with Philadelphia chromosome-positive leukemias in the post-transplant setting.
Atiq F; Broers AE; Andrews LM; Doorduijn JK; Koch BC; Van Gelder T; Versmissen J
Eur J Clin Pharmacol; 2016 Dec; 72(12):1539-1540. PubMed ID: 27561268
[No Abstract] [Full Text] [Related]
15. Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells.
Mishra S; Zhang B; Cunnick JM; Heisterkamp N; Groffen J
Cancer Res; 2006 May; 66(10):5387-93. PubMed ID: 16707466
[TBL] [Abstract][Full Text] [Related]
16. In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells.
Scappini B; Onida F; Kantarjian HM; Dong L; Verstovsek S; Keating MJ; Beran M
Cancer; 2002 May; 94(10):2653-62. PubMed ID: 12173333
[TBL] [Abstract][Full Text] [Related]
17. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells.
Nimmanapalli R; Fuino L; Stobaugh C; Richon V; Bhalla K
Blood; 2003 Apr; 101(8):3236-9. PubMed ID: 12446442
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
Thomas X; Dombret H
Leuk Lymphoma; 2008 Jul; 49(7):1246-54. PubMed ID: 18452076
[TBL] [Abstract][Full Text] [Related]
19. The ARF tumor suppressor in acute leukemias: insights from mouse models of Bcr-Abl-induced acute lymphoblastic leukemia.
Williams RT; Sherr CJ
Adv Exp Med Biol; 2007; 604():107-14. PubMed ID: 17695724
[TBL] [Abstract][Full Text] [Related]
20. Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells.
Carter BZ; Mak DH; Schober WD; Cabreira-Hansen M; Beran M; McQueen T; Chen W; Andreeff M
Blood; 2006 Feb; 107(4):1555-63. PubMed ID: 16254145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
